皓元医药：关于不提前赎回“皓元转债”的公告

Core Points - Haoyuan Pharmaceutical announced that its stock has triggered the conditional redemption clause for its convertible bonds due to the closing price exceeding 130% of the conversion price for 15 out of 30 trading days [2] - The company decided not to exercise the early redemption rights for the "Haoyuan Convertible Bonds" during the upcoming six-month period [2] - Future assessments for potential redemption will be conducted after May 20, 2026, if the redemption clause is triggered again [2]